Ayda Ahmadi | Pancreatic Cancer | Best Researcher Award

Published on by Oncology

Ms. Ayda Ahmadi | Pancreatic Cancer | Best Researcher Award 

Student | Sahand University of Technology | Iran

Ms. Ayda Ahmadi is an emerging young researcher in biomedical and pharmaceutical engineering whose academic performance, early research productivity, and strong technical training collectively position her as a promising candidate for a Best Researcher Award. Currently pursuing her M.Sc. in Chemical Engineering with a specialization in Pharmaceutical Engineering at Sahand University of Technology, she holds a solid academic foundation built on a high-performing B.Sc. in Biomedical Engineering (Biomaterials) from Khayyam University. Her hands-on experience includes two extensive 240-hour internships at Samen Pharmaceutical Company—where she gained valuable skills in pharmaceutical formulation, sterile production systems, GMP-based quality control, and laboratory documentation—and in a Dental Prosthesis Laboratory, where she developed practical expertise in biomaterials fabrication relevant to tissue engineering and biomedical device applications. Ayda’s research output reflects her focus on advanced drug delivery systems, nanotechnology, and biomaterials, demonstrated through significant works such as the preparation and characterization of silica nanoparticles and aerogels for smart drug delivery, the design of targeted nanocarriers for anticancer drug delivery to pancreatic tumors, and the study of calcium sulfate for treating bone infections in diabetic patients. With manuscripts submitted and under review, she shows early publication initiative and a clear commitment to building a strong scientific portfolio. Her technical proficiency across COMSOL Multiphysics, MATLAB, Aspen HYSYS, OriginPro, and data management tools further enhances her research capability, supported by multiple certifications. Ayda’s research interests—spanning nanostructure functionalization, controlled antibiotic release, and biomedical applications of engineered materials—align strongly with global research priorities in precision medicine and therapeutic innovation. Motivated to participate in international conferences and collaborative projects, she demonstrates ambition, discipline, and scientific curiosity, making her a suitable and competitive candidate for recognition in young researcher or early-career researcher award categories.

Profile: ORCID

Featured Publications

  1. Ahmadi, A., Souri, A., & Moghaddas, J. S. (2025). Preparation, characterization, and application of silica nanoparticles and silica aerogel in smart drug delivery systems. Manuscript submitted for publication.

  2. Ahmadi, A., Souri, A., & Moghaddas, J. S. (2025). Design and development of smart nanocarriers for targeted delivery of anticancer drugs to pancreatic tumors: A review study. Manuscript under review.

  3. Ahmadi, A. (2024). Investigation of the effect of calcium sulfate in the treatment of bone infections in diabetic patients. Unpublished research project, Khayyam University.

  4. Ahmadi, A. (2024). Surface modification of silica aerogel for drug delivery in the treatment of bone infection in diabetic patients. Unpublished research study, Sahand University of Technology.

  5. Ahmadi, A., Souri, A., & Moghaddas, J. S. (2024). Development of functionalized nanostructures for controlled antibiotic release in infectious diseases. Unpublished manuscript.

Ms, Ayda Ahmadi’s research advances next-generation drug delivery systems and biomaterial-based therapeutics, contributing to safer, more effective treatments for cancer and infectious diseases. Her innovative work in nanotechnology and smart drug carriers supports global medical innovation by improving targeted therapy, reducing side effects, and addressing critical healthcare challenges.

Jaweher Bday | Cancer Research | Best Researcher Award

Published on by Oncology

Ms. Jaweher Bday | Cancer Research | Best Researcher Award 

PhD Student | Higher Institute of Biotechnology of Monastir | Tunisia

Ms. Jaweher Bday is a highly promising PhD researcher in biotechnology with a robust specialization in immuno-oncology, demonstrating strong potential and clear suitability for a Best Researcher Award through her scientific rigor, technical depth, and impactful research outputs. Her academic journey—from a bachelor’s degree in molecular and cellular biology, a research master’s in cell biology and physiology, to an ongoing PhD at the Higher Institute of Biotechnology of Monastir—illustrates continuous progression and dedication to cancer research. She has completed several competitive international research internships in leading laboratories in France, including the Bio PeroxIL Laboratory at the University of Burgundy and the INSERM U1307 Laboratory at the University of Nantes, enhancing her expertise in cell death mechanisms, tumor biology, and advanced molecular techniques. Her publication record is strong and growing, with peer-reviewed articles in recognized journals on topics such as arginase regulation in HPV infection, hybrid cell-death induction in breast cancer models, and the role of nitric oxide pathways in cervical carcinogenesis, along with an additional submitted manuscript on HPV circulating markers. Jaweher’s scientific maturity is evidenced by her active participation in conferences, including oral and poster presentations at national and international oncology and toxicology meetings, reflecting substantial dissemination of her research. Beyond laboratory excellence, she demonstrates leadership through major roles in the Tunisian Association of Biotechnology Students, including serving as President and spearheading scientific events and innovation-focused programs. Her teaching activities, spanning workshops, directed courses, and hands-on training, further showcase her commitment to academic development and knowledge transfer. Equipped with advanced laboratory skills, strong analytical proficiency using tools like FlowJo, ImageJ, SPSS, and GraphPad, along with extensive training in scientific writing, publishing, quality management, and pedagogy, she embodies the qualities of an emerging researcher with both scientific impact and community engagement. Overall, her achievements, productivity, international exposure, and leadership make her an excellent candidate for a Best Researcher Award.

Profile: ORCID

Featured Publications

  1. Souid, M., Bday, J., Souissi, S., Ghedira, R., Gabbouj, S., Shini-Hadhri, S., Toumi, D., Bergaoui, H., Zouari, I., Faleh, R., Zakhama, A., & Hassen, E. (2023). Arginase is upregulated in healthy women infected by oncogenic HPV types. Biomarkers, 28(7), 628–636.

  2. Bday, J., Souid, M., Pires, V., Gabbouj, S., Véjux, A., Lizard, G., & Hassen, E. (2025). Arginase activity inhibition with thymoquinone induces a hybrid type of cell death in MDA-MB-231 cell line. Journal of Biochemical and Molecular Toxicology, 39(2), e70130.

  3. Bday, J., Souid, M., Farhat, K. H., Macherki, Y., Ghedira, R., Gabbouj, S., Shini-Hadhri, S., Faleh, R., & Hassen, E. (2025). Involvement of endothelial nitric oxide synthase (eNOS) and nitric oxide (NO) levels in precancerous and cancerous cervical lesions. Nitric Oxide, 159, 176–185.

  4. Souid, M., Ghedira, R., Bday, J., Gabbouj, S., Shini-Hadhri, S., Hajji, A., Faleh, R., & Hassen, E. (Under review). Human Papillomavirus-16 circulating markers distribution among unvaccinated women. Infectious Diseases Now.

  5. Bday, J., Souid, M., Pires, V., Véjux, A., Lizard, G., & Hassen, E. (2025). Hybrid cell-death mechanisms in breast cancer: Insights from thymoquinone-mediated arginase inhibition. Manuscript in preparation.

Ms. Jaweher Bday’s work advances immuno-oncology by uncovering novel cellular and molecular mechanisms that can drive more precise cancer diagnostics and targeted therapies. Her research contributes to global health by improving understanding of HPV-related cancers and breast cancer biology, supporting innovations that can shape future clinical and translational applications. Through scientific leadership, teaching, and community engagement, she helps strengthen research capacity and fosters the next generation of biotechnology innovators.

Melissa Christiaens | Cervical Cancer | Best Researcher Award

Published on by Oncology

Dr. Melissa Christiaens | Cervical Cancer | Best Researcher Award

Radiation-Oncology | University Hospitals Leuven | Belgium

Dr. Melissa Christiaens is a highly accomplished Radiation Oncologist recognized for her contributions to the advancement of radiotherapy and clinical oncology research. With extensive experience in oncological treatment, she has played a key role in integrating evidence-based radiotherapy techniques into modern cancer care. Her professional expertise spans across radiotherapy quality assurance, pediatric oncology, gynecologic cancers, and multidisciplinary tumor management. As an active member of several leading scientific organizations—including the European Society for Radiotherapy and Oncology, the Paediatric Radiation Oncology Society, the European Society of Gynaecological Oncology, the EuroEwing Consortium, and the Connective Tissue Oncology Society—she consistently collaborates in large-scale international research networks to improve patient outcomes and optimize therapeutic protocols. Her research interests focus on clinical trials in radiotherapy, immuno-oncology integration, and precision treatment strategies for rare and complex cancers. Dr. Christiaens has contributed to numerous high-impact peer-reviewed journals such as The Lancet, Radiotherapy and Oncology, BMC Cancer, and Gynecologic Oncology, where her publications have enhanced the scientific understanding of cancer treatment outcomes, safety, and innovation. Her research skills encompass clinical data interpretation, protocol development, treatment optimization, and evidence synthesis—supported by her commitment to maintaining the highest standards of clinical excellence. Throughout her career, she has demonstrated exceptional leadership in oncology research and education, promoting collaboration and innovation within the global cancer research community. Her achievements continue to inspire advancements in patient-centered cancer therapy and clinical radiobiology. Her enduring scientific legacy is reflected through 1,417 citations, 25 documents, and an h-index of 12, underscoring her influential role in advancing the frontiers of clinical radiotherapy, oncology innovation, and multidisciplinary cancer research.

Profiles: Google Scholar | Scopus | ResearchGate

Featured Publications

1. Pötter, R., Tanderup, K., Schmid, M. P., Jürgenliemk-Schulz, I., Haie-Meder, C., & Christiaens, M., et al. (2021). MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): A multicentre prospective cohort study. The Lancet Oncology, 22(4), 538–547. Cited by: 613

2. Zhang, H., Ahearn, T. U., Lecarpentier, J., Barnes, D., Beesley, J., Qi, G., Jiang, X., & Christiaens, M., et al. (2020). Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 52(6), 572–581. Cited by: 466

3. Lorusso, D., Xiang, Y., Hasegawa, K., Scambia, G., Leiva, M., Ramos-Elias, P., & Christiaens, M., et al. (2024). Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18). The Lancet, 404(10460), 1321–1332. 
Cited by: 323

4. Ajithkumar, T., Horan, G., Padovani, L., Thorp, N., Timmermann, B., Alapetite, C., & Christiaens, M., et al. (2018). SIOPE–Brain tumor group consensus guideline on craniospinal target volume delineation for high-precision radiotherapy. Radiotherapy and Oncology, 128(2), 192–197. Cited by: 113

5. De Ruysscher, D., Sharifi, H., Defraene, G., Kerns, S. L., & Christiaens, M., et al. (2013). Quantification of radiation-induced lung damage with CT scans: The possible benefit for radiogenomics. Acta Oncologica, 52(7), 1405–1410. Cited by: 74

Ping Dai | Cancer Therapy | Best Researcher Award

Published on by Oncology

Dr. Ping Dai | Cancer Therapy | Best Researcher Award

Tongji University | China

AUTHOR PROFILE

SCOPUS ID

🏥DR. PING DAI: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Dr. Ping Dai’s journey in medicine began with a Diploma of Higher Education in Clinical Medicine from Harbin University, followed by a Bachelor’s degree at Qiqihar Medical University. She excelled further with an Outstanding Master’s Degree in Oncology from Shihezi University, and culminated her academic path with a Doctorate in Molecular Radiation Oncology (Dr. Med, Magna Cum Laude) from the prestigious Heidelberg University in Germany—underscoring a profound commitment to academic excellence and clinical innovation.

🩺PROFESSIONAL ENDEAVORS

With over a decade of clinical and research experience, Dr. Dai currently serves as Assistant Director at the Shanghai Fourth People’s Hospital Affiliated to Tongji University. Her career spans multiple critical roles—oncologist, clinical researcher, and international doctoral candidate at the German Cancer Research Centre (DKFZ)—fusing global perspectives with localized healthcare innovation.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON BIOMARKERS  IN CANCER THERAPY

Dr. Dai’s research centers on radiation oncology, immunotherapy-related thyroid dysfunction, and tumor treating fields (TTFields). Notably, her recent studies explore PD-1/PD-L1 inhibitor-induced thyroid dysfunction as a biomarker for efficacy in advanced lung cancer therapy, published in BMC Cancer and Heliyon. She also leads groundbreaking simulation research on electrodynamic tumor interactions, merging clinical oncology with bioengineering insight.

🌍IMPACT AND INFLUENCE

Dr. Dai’s cross-continental experience—from China to Germany—bridges Eastern and Western oncology practices. Her insights contribute to both clinical protocol improvements and space-radiation biology, collaborating with institutions such as the European Space Agency and Heidelberg Ion Beam Therapy Center. She plays a vital role in shaping translational cancer science and space medicine.

🏆ACADEMIC CITES, ACCOLADES AND RECOGNITION

  • Lead or corresponding author in high-impact journals: Cancer Letters (IF 9.7), APL Bioengineering (IF 6.6), and Frontiers in Oncology.

  • Honored with Outstanding Master’s Graduate award.

  • Latin honors “Magna Cum Laude” for doctoral studies in Germany.

  • Recognized as equal-first author and corresponding author in multiple prestigious publications.

🏆LEGACY AND FUTURE CONTRIBUTIONS

Dr. Dai is establishing a legacy of translational research at the intersection of radiation therapy, immunology, and biomarker discovery. Her future pursuits aim to:

  • Advance predictive markers for immunotherapy outcomes.

  • Explore MSC-based interventions against radiation-induced myelotoxicity.

  • Lead multinational clinical collaborations in cancer therapy and space radiation countermeasures.

🧬CONCLUSION

Dr. Ping Dai is an emerging force in molecular oncology and translational medicine. With a rich academic foundation, strong clinical acumen, and a forward-thinking research vision, she is contributing impactful solutions to global oncology and radiobiology challenges.

📊🔬NOTABLE PUBLICATION:

Thyroid dysfunction as a predictor of PD-1/PD-L1 inhibitor efficacy in advanced lung cancer

Authors: Yanling Wang, Xiaoping Ma, Jia Ma, Jing Li, Zhiyi Lin, Wei Gao, Ping Gong, Ping Dai
Journal: BMC Cancer
Year: 2025

Comprehensive Simulations of Intracellular Electric Fields during Exposure to Tumor Treating Fields (TTFields)

Authors: Kaida Liu, Ping Dai, Zirong Liu, Haohan Fang, Xing Li, Wei Gao
Journal: Frontiers in Oncology
Year: 2025 (Accepted)

Electrodynamic Interaction between Tumor Treating Fields and Microtubule Electrophysiological Activities

Authors: Xing Li, Kaida Liu, Haohan Fang, Zirong Liu, Yuchen Tang, Ping Dai
Journal: APL Bioengineering
Year: 2024

A theoretical study on evaluating brain tumor changes in tumor treating fields therapy by impedance detection

Authors: Xing Li, Kaida Liu, Haohan Fang, Rongzi Liu, Wei Gao, Ping Dai
Journal: Frontiers in Oncology
Year: 2024